Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Caroline Dudkowski"'
Publikováno v:
European Journal of Clinical Pharmacology
Purpose The aim of this study is to determine the pharmacokinetics (PK) and pharmacodynamics (PD) of a single 12.5- or 25-mg dose of alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, in pediatric (children and adolescents) and adult subjects wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5af0ace8985a5f79fee716319fa69536
https://doi.org/10.1007/s00228-016-2175-1
https://doi.org/10.1007/s00228-016-2175-1
Publikováno v:
Clinical Pharmacology in Drug Development
Azilsartan medoxomil is a long‐acting angiotensin II receptor blocker used to treat hypertension as monotherapy or in fixed‐dose combination (FDC) with chlorthalidone. This study assessed the effects of food intake on the plasma pharmacokinetics
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3d993dddbe5a6f6813706a2e7aa6000
https://doi.org/10.1002/cpdd.249
https://doi.org/10.1002/cpdd.249
Publikováno v:
European Journal of Clinical Pharmacology
Purpose This open-label, multicenter, single-dose study characterized the pharmacokinetics and short-term safety of azilsartan medoxomil (AZL-M) in hypertensive pediatric subjects (12–16 years [cohort 1a; n = 9]; 6–11 years [cohort 2; n = 8]; 4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d560b7412f6a5bc24db2df132f0827e
https://doi.org/10.1007/s00228-015-1987-8
https://doi.org/10.1007/s00228-015-1987-8
Autor:
Dyal C. Garg, Zhen Zhao, Richard A. Preston, Caroline Dudkowski, Alberto B. Alonso, Aziz Karim
Publikováno v:
Journal of Clinical Pharmacology
Azilsartan medoxomil (AZL‐M) is a potent angiotensin II receptor blocker that decreases blood pressure in a dose‐dependent manner. It is a prodrug that is not detected in blood after its oral administration because of its rapid hydrolysis to the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::caf18e13ad326b6d9c1dcadf6d60b773
https://pubmed.ncbi.nlm.nih.gov/28750149
https://pubmed.ncbi.nlm.nih.gov/28750149
Publikováno v:
Clinical Pharmacokinetics
Background and Objective Azilsartan medoxomil (AZL-M) is an angiotensin II receptor blocker approved to treat hypertension. After oral dosing, AZL-M is quickly hydrolyzed to azilsartan (AZL). The aims of this study were to assess the effects of age,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93d810b5c358f398af024ea5c68523fc
https://pubmed.ncbi.nlm.nih.gov/26507722
https://pubmed.ncbi.nlm.nih.gov/26507722
Autor:
Yue-Fen Wang, Dai-chang Yang, Ji Y. Zhang, Jinhua Yuan, Susan K. Paulson, Caroline Dudkowski, Ming Chang, Alan P. Breau
Publikováno v:
Journal of Mass Spectrometry. 35:1259-1270
The metabolism of the anti-inflammatory drug Celecoxib in rabbits was characterized using liquid chromatography (LC)/tandem mass spectrometry (MS/MS) with precursor ion and constant neutral loss scans followed by product ion scans. After separation b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a492812cc89a017f3fcc4e564aa218ee
https://doi.org/10.1002/1096-9888(200011)35:11<1259::aid-jms57>3.0.co
https://doi.org/10.1002/1096-9888(200011)35:11<1259::aid-jms57>3.0.co
Autor:
Caroline Dudkowski, Richard A. Preston, Domenic A. Sica, Oliver Lenz, Aziz Karim, Zhen Zhao, Dyal C. Garg
Publikováno v:
Clinical pharmacokinetics. 52(5)
Azilsartan medoxomil (AZL-M) is a potent angiotensin II receptor blocker that decreases blood pressure in a dose-dependent manner. It is a pro-drug and not detected in blood after oral administration because of rapid hydrolysis to the active moiety,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e0955f09466ff4d4511a0eb2ec6da9b
https://pubmed.ncbi.nlm.nih.gov/23575872
https://pubmed.ncbi.nlm.nih.gov/23575872